Home » Stocks » CDAK

Codiak BioSciences, Inc. (CDAK)

Stock Price: $26.60 USD 0.73 (2.82%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $25.77 -0.83 (-3.12%) Jan 22, 4:30 PM
Market Cap 482.71M
Revenue (ttm) 622
Net Income (ttm) -94.46M
Shares Out 18.59M
EPS (ttm) -5.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $26.60
Previous Close $25.87
Change ($) 0.73
Change (%) 2.82%
Day's Open 25.72
Day's Range 25.17 - 27.90
Day's Volume 104,273
52-Week Range 7.90 - 32.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties –

GlobeNewsWire - 3 weeks ago

– exoIL-12 resulted in no local or systemic treatment-related adverse events –

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a n...

GlobeNewsWire - 2 months ago

– Human clinical testing now underway with Codiak's first two candidates, exoIL-12™ and exoSTING™ –

GlobeNewsWire - 2 months ago

– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo –

Seeking Alpha - 3 months ago

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

Other stocks mentioned: ALGS, ARRY, EBC, OPT, PRAX, SPEL, TARS
Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Codiak BioSciences, Inc. (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines...

About CDAK

Codiak BioSciences is harnessing exosomes?natural intercellular messengers?to pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including i... [Read more...]

Industry
Biotechnology
IPO Date
Oct 14, 2020
CEO
Douglas Williams
Employees
101
Stock Exchange
NASDAQ
Ticker Symbol
CDAK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CDAK stock is "Strong Buy." The 12-month stock price forecast is 35.00, which is an increase of 31.58% from the latest price.

Price Target
$35.00
(31.58% upside)
Analyst Consensus: Strong Buy